20.09.2022 | ASO Author Reflections
ASO Author Reflections: Gamma-Aminobutyric Acid Type A Receptor Subunit Delta as a Potential Therapeutic Target in Gastric Cancer
verfasst von:
Koichi Sawaki, MD, PhD, Mitsuro Kanda, MD, PhD, FACS, Yasuhiro Kodera, MD, PhD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
Despite advances in treatment, patients with advanced gastric cancer (GC) have poor prognosis and there is an urgent need for novel therapies. Dysregulation of several molecules has been shown to be associated with GC progression, metastasis, and relapse, and some of them have been successfully targeted for the treatment of GC.
1,2 Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain, where it acts at GABA-A receptors (GABA
ARs). Recent studies have revealed possible roles for GABA and GABA type A receptor subunit delta (GABRD) in the development and progression of various cancers;
3,4 however, the expression pattern, biological activity, and potential therapeutic value of these proteins in GC has not yet been determined. …